TD Cowen raised the firm’s price target on PTC Therapeutics (PTCT) to $38 from $33 and keeps a Hold rating on the shares. The firm said the company continues to execute well with Upstaza s PDUFA on November 13th and sepiapterin’s set for July 2025. Cowen anticipates approval for both.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT: